Dr. Lal Pathlabs Limited — Investor Presentation 2021

May 21, 2021

==> picture [611 x 65] intentionally omitted <==

May 21, 2021

The National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai - 400051

The Bombay Stock Exchange Limited 15[th] Floor, Phiroze Jeejeeboy Towers Mumbai – 400001

Subject: Earnings Presentation on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021

Dear Sir/Madam,

Please find attached herewith a copy of Company's Q4/ FY 2021 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021.

We request you to please take the same on record.

Thanking You,

==> picture [281 x 114] intentionally omitted <==

Encl: As above

==> picture [609 x 67] intentionally omitted <==

==> picture [720 x 60] intentionally omitted <==

Dr. Lal PathLabs Limited (DLPL) Q4 FY21 Results Presentation May 21, 2021

==> picture [720 x 91] intentionally omitted <==

Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

2

Q4 FY21 Snapshot

==> picture [592 x 233] intentionally omitted <==

----- Start of picture text -----

42.9% 101.7% 161.0%
INR 431.0 Cr INR 129.5 Cr INR 85.1 Cr
Revenues Normalised EBITDA PAT
33.3% 34.7%
~5.9 mn ~15.1 mn
Patients Samples
----- End of picture text -----

Q4 FY21 is not comparable to Q4 FY20 due to Nationwide lock-down in March 2020

==> picture [6 x 8] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

==> picture [79 x 26] intentionally omitted <==

Table of Contents

5 6 8 9 10 12 13 14 16 27 29

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Dr. Lal PathLabs – At a Glance
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Overview of Dr. Lal PathLabs
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Key Performance Highlights
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Financials
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Financial Highlights
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Operating Highlights
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Management Commentary
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Vibrant Outlook
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Corporate Overview
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Shareholding
----- End of picture text -----

==> picture [264 x 24] intentionally omitted <==

----- Start of picture text -----

Contact Us
----- End of picture text -----

DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs Limited would not be liable for any action undertaken based on such ‘forward-looking’ statements and does not commit to revising/updating 4 thempublicly.

==> picture [79 x 26] intentionally omitted <==

Dr. Lal PathLabs – At a Glance

India’s Leading & Trusted Diagnostics Company	Largest diagnostics*			15% 3 Year Revenue CAGR			22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21
70+ years of experience	chain in the
in the field of diagnostics 85.7 Mn patients serviced in last 5 years 30 NABL accredited Labs; National Reference Lab accredited by CAP	country with PAN India presence and consistent track record of quality and growth			~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spread out network			Rs 985.9 Cr. Cash & Investments as on 31st Mar 21 CRISIL AA- /Stable Long Term Rating; Strength of Balance Sheet 5,008 Pathology & Radiology tests; Comprehensive Test menu

As on March 31, 2021

*Largest on the basis of Revenue and presence

==> picture [79 x 26] intentionally omitted <==

5

Overview of Dr. Lal PathLabs

==> picture [37 x 42] intentionally omitted <==

==> picture [41 x 31] intentionally omitted <==

==> picture [638 x 179] intentionally omitted <==

----- Start of picture text -----

Established brand Pan-India integrated Varied Offerings Unique and successful
coverage operating model
231 clinical labs (including
National Reference Lab at Catalogue of 471 test panels, Scalable model integrated
Established consumer
Delhi and Regional Reference 2,590 pathology tests and through centralised IT
healthcare brand in diagnostic
lab at Kolkata), 3,705 Patient 1,947 radiology and platform allows for network
services
Service Centers (PSCs) and cardiology tests expansion
9,247 Pick-up Points (PUPs)
----- End of picture text -----

Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

==> picture [79 x 26] intentionally omitted <==

As on March 31, 2021

6

COVID, COVID Allied & Non-COVID Revenue

==> picture [641 x 231] intentionally omitted <==

----- Start of picture text -----

Rs. Cr. • Non-COVID business grew at a phenomenal
382 growth rate of 26.8% in Q4 FY21
347 355
• COVID portfolio contribution to total revenue
declined to 11.2% in Q4 FY21 from 21.6% in
Q3 FY21 due to regulations on pricing of RT-
209
PCR testing
• COVID Allied business in Q4 FY21 was at
74 81
56 43 12.5% of total COVID portfolio.
1 11 16 6 • 4.5 lac COVID RTPCR tests conducted in Q4
FY21 and 14.9 lac in FY21
Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21
• RT-PCR test being conducted in 14 labs across
Non COVID COVID COVID Allied the country
----- End of picture text -----*

• *COVID includes RTPCR and Antibody tests

• **COVID Allied includes IL-6 & D-Dimer

==> picture [79 x 26] intentionally omitted <==

7

Key Performance Highlights

==> picture [649 x 40] intentionally omitted <==

----- Start of picture text -----

During Q4 FY21:
----- End of picture text -----

• Revenues enhanced by 42.9% Y-o-Y to Rs. 431.0 crore

• Normalised EBITDA (after eliminating the impact of stock based compensation & CSR) came in at Rs. 129.5 crore

• Profit After Tax at Rs. 85.1 crore, higher by 161% over same period last year

• Final dividend of Rs. 8 per equity share of Rs. 10 each approved by the Board of Directors

==> picture [649 x 41] intentionally omitted <==

----- Start of picture text -----

Cash, FDs and Mutual Funds at Rs. 985.9 crore as on March 31, 2021, an increase of Rs. 241.7 crore over
March 31, 2020
----- End of picture text -----

==> picture [649 x 39] intentionally omitted <==

----- Start of picture text -----

Non-COVID business achieves a phenomenal increase with 26.8% growth Y-o-Y; COVID testing surged again in
March as caseloads rise across the country
----- End of picture text -----

• Non-COVID business revenues stood at Rs. 382.5 crore in Q4 FY21

• Patient volumes grew by 33.3% Y-o-Y to 5.9 million

• The bundled test portfolio ‘Swasthfit’ contributed 16.9% to revenue in Q4 FY21

==> picture [79 x 26] intentionally omitted <==

8

Financials

Particulars (Rs. Cr.)	Q4 FY21	Q4 FY20	Gr %	FY21	FY20	Gr %
Revenue	431.0	301.7	42.9%	1,581.3	1,330.4	18.9%
Expenditure EBITDA Stock based comp. & CSR cost	309.0 122.0 7.5	244.4 57.3 6.9		1,145.0 436.3 26.3	986.8 343.6 22.0
			112.9%			27.0%
Normalised EBITDA	129.5	64.2	101.7%	462.6	365.6	26.5%
Normalised Margins Other Income	30.0% 13.5	21.3% 12.0		29.3% 51.3	27.5% 55.0
PBT	110.8	45.4	144.1%	394.4	310.5	27.0%
Margins	25.7%	15.0%		24.9%	23.3%
PAT	85.1	32.6	161.0%	296.5	227.6	30.3%
Margins	19.7%	10.8%		18.8%	17.1%
EPS (Basic)	10.10	3.94	156.3%	35.33	27.42	28.8%
EPS (Diluted)	10.07	3.93	156.2%	35.25	27.37	28.8%

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

==> picture [79 x 26] intentionally omitted <==

9

Financial Highlights

==> picture [313 x 134] intentionally omitted <==

----- Start of picture text -----

+42.9%
431.0
301.7
Revenue
Q4 FY20 Q4 FY21
----- End of picture text -----

All figures in Rs. Crore

• In Q4 FY21, Revenue improved to Rs. 431.0 crore, higher by 42.9% Y-o-Y led by :

• 33.3% increase in volumes

• Growth in Non-COVID business and uptick in COVID testing volumes in March

• Realisation per patient in Q4 FY21 stood at Rs. 733, higher as against to Rs. 684 in Q4 FY20

==> picture [309 x 125] intentionally omitted <==

----- Start of picture text -----

+101.7%
Normalised EBITDA (after 129.5
eliminating the impactof
stock based compensation, 64.2
and CSR costs)
Q4 FY20 Q4 FY21
----- End of picture text -----

• Normalised operating EBITDA (after eliminating the impact of stock based compensation and CSR costs) came in at Rs. 129.5 crore in Q4 FY21, an increase by 101.7% Y-o-Y

• Q4 FY21 Normalised EBITDA margin (after eliminating the impact of stock based compensation and CSR costs) came in at 30.0%

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be 10 influenced by certain occurrences in that quarter

==> picture [79 x 26] intentionally omitted <==

Financial Highlights

All figures in Rs. Crore

==> picture [696 x 297] intentionally omitted <==

----- Start of picture text -----

All figures in Rs. Crore
+144.1%
• PBT for Q4 FY21 stood at Rs. 110.8 crore as compared to
110.8
Rs. 45.4 crore reported in the same quarter last year,
representing a growth of 144.1%
PBT 45.4 • Q4 FY21 PBT margin came in at 25.7% vs. 15.0% in the
corresponding quarter of last year
Q4 FY20 Q4 FY21
+161.0%
• In Q4 FY21, PAT was at Rs. 85.1 crore, higher by 161.0%
85.1
as compared to Rs. 32.6 crore in Q4 FY20
PAT • Q4 FY21 PAT margin was at 19.7% against 10.8% in Q4
32.6 FY20
Q4 FY20 Q4 FY21
----- End of picture text -----

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be 11 influenced by certain occurrences in that quarter

==> picture [79 x 26] intentionally omitted <==

Operating Highlights

==> picture [688 x 288] intentionally omitted <==

----- Start of picture text -----

No. of Clinical Laboratories No. of PSCs No. of PUPs
+38 +1,552 +3,623
193 200 216 231 3,095 3,705 6,426 6,995 9,247
2,569 5,624
2,153
FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21
No. of Patients (Mn) No. of Samples (Mn)
+33% +43%
17.6 19.4 20.3 47.7 49.7
15.2 41.8
34.7
FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21
----- End of picture text -----

==> picture [11 x 7] intentionally omitted <==

----- Start of picture text -----

12
----- End of picture text -----

==> picture [79 x 26] intentionally omitted <==

Management Commentary

Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman

“Even though the concluding quarter of FY21 was marked by the second wave of COVID-19 pandemic in India, we have ensured that our non-COVID business has shown growth. The COVID business started increasing by the end of the quarter due to the growing caseload of COVID cases. In our bid to sustain the market leadership position, we continue to expand test menu, penetrate into newer geographies and strengthen our hold in existing regions.”

Commenting on the results announcement, Dr. Om Manchanda, Managing Director

“Just when everything was returning back to normalcy, India was unfortunately hit by the second wave of pandemic, although this time we were better prepared to manage the crisis given our inherent strengths and sheer experience. Our teams have worked relentlessly to serve all the patients during these unprecedented times and providing them with best quality diagnostic services at affordable prices.”

Commenting on the results announcement, Bharath Uppiliappan, Chief Executive Officer

“Despite the emerging challenges faced in Q4, being a pan-India, organized diagnostics player, Dr. Lal PathLabs is well placed to grow both in COVID and non-COVID businesses. Our strategic efforts of expanding in the West and South continues, while our test menu is constantly getting enhanced. We are confident of realizing our growth aspirations going forward driven by increased demand for quality diagnostics.”

==> picture [79 x 26] intentionally omitted <==

13

Vibrant Outlook

Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets

==> picture [648 x 247] intentionally omitted <==

----- Start of picture text -----

Target
to grow
Evaluate best fit inorganic Deeper Penetration within the
ahead
opportunities in South & West North, East & Central Indian
of the
markets
industry
Higher contribution from bundling of
tests – ‘Swasthfit’
----- End of picture text -----

==> picture [79 x 26] intentionally omitted <==

14

Leveraging digital to make life easier for patient

==> picture [45 x 45] intentionally omitted <==

==> picture [49 x 49] intentionally omitted <==

==> picture [45 x 45] intentionally omitted <==

==> picture [44 x 36] intentionally omitted <==

==> picture [60 x 47] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

• Logistics Lab Operations Business

• Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan

• • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients package booking and download Mobile App for Track with • Quick recovery in

• • Integrated payment • Online payment, current and Route Traceability & centralized LIMS for case of disaster gateway for online order related historical test Field Executive higher Output and • Real time Data payment notifications at reports Tracking faster processing, Replication

• • Self Report printing various touch points • Trend chart along • Real Time visibility built in analytics and between sites Kiosks for 24 by 7 • Integrated Cross with Cumulative of patient samples Business Intelligence • Centrally Report printing Channel Reporting capabilities Hosted and similar to a bank communication with • Find a Lab near you real time ATM strong automated • Self Monitoring – monitored backend using cloud, My Wellness predictive analytics & AI

• Phlebo Mobile App for home collection booking along with route plan.

==> picture [79 x 26] intentionally omitted <==

15

==> picture [720 x 65] intentionally omitted <==

Corporate Overview

==> picture [278 x 227] intentionally omitted <==

==> picture [79 x 26] intentionally omitted <==

16

Vision, Mission & Values

VISION

==> picture [683 x 290] intentionally omitted <==

----- Start of picture text -----

Customer First
Be the most trusted healthcare partner, enabling
healthier lives Ethics & Integrity
VALUES Quality
To be the undisputed market leader by providing
Accountability
accessible, affordable, timely and quality healthcare,
diagnostics, applying insights and cutting edge
technology to create value for all stakeholders Empathy & Compassion
MISSION
17
----- End of picture text -----

DLPL Strategy for future growth

==> picture [648 x 332] intentionally omitted <==

----- Start of picture text -----

Strengthen
Expansion in
Existing
1 Offering 2
Operations
Expand
management of
Geographic
hospital based
4 expansion 3
and clinical
laboratories
18
----- End of picture text -----

DLPL Strategy for future growth

==> picture [690 x 46] intentionally omitted <==

Strengthen Existing Operations Expansion in Offering Boosting quality & reliability Improve breadth of standards diagnostic testing

Improving turnaround times for testing

Cutting edge technology Preventive healthcare screening Chronic & Lifestyle disease mgmt. services Expand reach in corporate segment

Grow basic radiology practice Online initiatives and data analytics Investment in branding

Expand management of hospital based and clinical laboratories

Tap incremental contracts for in sourcing test of hospitals and other clinical laboratories

Tap polyclinics

Geographic expansion

Focus city & cluster approach

Set up more clinical laboratories Set up Regional Reference Laboratories Consider alliances and acquisitions

==> picture [79 x 26] intentionally omitted <==

19

Consistent investments in R&D

DSIR recognized In House R&D unit with an experienced team of research scientists and doctors

==> picture [145 x 138] intentionally omitted <==

==> picture [44 x 7] intentionally omitted <==

==> picture [44 x 6] intentionally omitted <==

R&D Collaboration with marquee institutions Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium tuberculosis and mycoabacterial species

==> picture [109 x 42] intentionally omitted <==

CSIR-Institute of Genomics and Integrative Biology for acquisition of know-how for 27 diagnostic assays

Successful commercialization of tests

==> picture [68 x 55] intentionally omitted <==

• Spino-Bulbar-Muscular Atrophy

• Sickle Cell Trio Prenatal Mutation Detection

• Sanger Sequencing, Single Variant

• Leigh Syndrome Mitochondrial Mutation Detection

• Episodic Ataxia Type 2

==> picture [11 x 8] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

==> picture [79 x 26] intentionally omitted <==

Genevolve: The Genomics initiative

==> picture [170 x 53] intentionally omitted <==

GENEVOLVE brings the dawn of a new era of Genomic testing!

Genevolve: Genomics division focuses on Genetic testing

Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/ Post-natal

Tests are carried out using cutting edge technologies such as Next Generation Sequencing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others

==> picture [56 x 56] intentionally omitted <==

==> picture [54 x 9] intentionally omitted <==

----- Start of picture text -----

New Tests
----- End of picture text -----

• Sperm DNA

• Y Chromosome

==> picture [63 x 66] intentionally omitted <==

----- Start of picture text -----

New Tie-ups
----- End of picture text -----

==> picture [34 x 40] intentionally omitted <==

ONCOPATH

• Caris MI (USA) • Niche

• • Caris Tumor Segmentation Seek

PAN India network of clinical laboratories, collection centers and pick- up points makes Dr. Lal PathLabs the most reliable genetic testing service provider in India

==> picture [79 x 26] intentionally omitted <==

21

In-house adoption of Digital Histopathology

• Reporting of Digital Breast cancer Panels using AI based algorithms

• Digital Histopathology for remote routine reporting

==> picture [288 x 285] intentionally omitted <==

Opportunities created by Digital Histopathology

•Enhanced access to second opinion, synchronous review of slides

• •Enhanced quality of reporting

• •Potential for insourcing services

• •Leveraging Artificial Intelligence for Histopathology

• •Potential for de-centralization of histopathology reporting

==> picture [79 x 26] intentionally omitted <==

22

Highest Quality Standards in the Industry

==> picture [678 x 302] intentionally omitted <==

----- Start of picture text -----

100+ Quality Digitally enabled
Real time quality Risk based improvement solutions
control quality assurance meetings on a daily implemented for
monitoring framework basis with the quality audits
network partners and trainings
Best in the Industry CAP Proficiency Testing Score at 98.3% for National Reference Lab
Consistently high EQAS Performance Testing Score at 98.7% for Satellite Labs
NABL Accreditation granted to 14 Labs for processing Covid-19 samples
23
----- End of picture text -----

Best in class Logistics and Supply Chain management

==> picture [720 x 335] intentionally omitted <==

----- Start of picture text -----

Real
Real time
time
service
sample
monitoring
tracking Control
tower
Real time
Automated
Field
Cash Productivity
Executive
and route
collection
tracking
planning
process
with clients visibility
24
----- End of picture text -----

Enhanced Customer Experience in Home Collection

==> picture [648 x 336] intentionally omitted <==

----- Start of picture text -----

Auto Routing engine to
dynamically allocate the
booking to nearest available
phlebotomist
Real time slot confirmation Real time phlebo visibility to
to patient the patient
Variable model which grows ECG at home service
with business volume launched in select cities
Automated and scalable
system
25
----- End of picture text -----

Experienced Management team

==> picture [702 x 181] intentionally omitted <==

----- Start of picture text -----

(Hony.) Brig. Dr. ArvindLal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel
Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer
Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg
Company Secretary and Compliance
Chief Operating Officer Chief Information Officer Chief Human Resources Officer
Officer
----- End of picture text -----

==> picture [79 x 26] intentionally omitted <==

26

Shareholding as of 31st March, 2021

29.6% FIIs, FPIS & Foreign Company 8.8% 55.2% Others Promoter and Promoter Group 6.4% Mutual Funds*

*Mutual Funds includes Alternate Investment Funds as well

==> picture [79 x 26] intentionally omitted <==

27

Key Awards & Recognition

==> picture [70 x 60] intentionally omitted <==

==> picture [76 x 43] intentionally omitted <==

==> picture [45 x 60] intentionally omitted <==

==> picture [93 x 52] intentionally omitted <==

==> picture [82 x 35] intentionally omitted <==

==> picture [76 x 37] intentionally omitted <==

Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The Data Quest Technology VC Circle Healthcare and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best Personality of the Year, 2020’ Management Awards 2020 Sciences & Healthcare in Implementation of Diagnostic Company by FICCI – Emerging Corporates Technology

==> picture [118 x 36] intentionally omitted <==

Computerworld Honors Laureate Program, 2012

==> picture [94 x 50] intentionally omitted <==

Frost and Sullivan 4th Annual India Healthcare Excellence Award, 'Diagnostic Service Provider Company of the Year 2012'

==> picture [102 x 31] intentionally omitted <==

Franchise India Excellence Award in Hall of Fame Category (2011, 2012)

==> picture [44 x 65] intentionally omitted <==

Franchisor of the Year (Healthcare) - Franchise Plus Awards 2010

==> picture [69 x 55] intentionally omitted <==

Padma Shri – (Hony) Brig. Dr. Arvind Lal (2009)

==> picture [79 x 26] intentionally omitted <==

28

Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 471 test panels, 2,590 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2021.

As on March 31, 2021, DLPL’s has 231 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,705 Patient Service Centers (PSCs) and 9,247 Pick-up Points (PUPs). In FY20 & FY21, DLPL collected and processed approximately 47.7 million samples and 49.7 million samples from approximately 19.4 million and 20.3 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388

Website: https://www.lalpathlabs.com

Ved Goel / Rajat Kalra Siddharth Rangnekar / Nishid Solanki For further Dr. Lal PathLabs Limited CDR India information Tel: +91 124 301 6500 Tel: +91 22 66451209 / 1221 please contact: Fax: +91 124 423 4468 Fax: +91 22 66451213 E-mail: ved.goel@lalpathlabs.com/ rajat.kalra@lalpathlabs.com Email: siddharth@cdr-india.com / nishid@cdr-india.com

==> picture [79 x 26] intentionally omitted <==

29